Stay updated with breaking news from Thomas Theuringer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Start of worldwide diagnostic use follows the launch of upgraded EZ2 Connect for research use in 2021, builds on the success of EZ1 Connect platform found in thousands of labs worldwide EZ2
Partnership to leverage the Helix Laboratory Platform powered by QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise Addressing health burden in neuro-degenerative
therascreenKRAS RGQ PCR kit approved as a companion diagnostic to aid in identifying non-small cell lung cancer (NSCLC) patients eligible for treatment with KRAZATI (adagrasib) KRAS mutations
NeuMoDx MPXV Test Strip enables researchers to quickly identify both clade I II of the monkeypox virus Dual-target design to reduce false negatives Multiplex test strengthens QIAGEN's
Q3 2022: Net sales of $500 million (-7% at actual rates, 0% at constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.53 Net sales at CER of $533 million vs.